Monoclonal antibodies (mAbs) have an essential role in biomarker validation and diagnostic assays. A barrier to pursuing these applications is the reliance on immunization and hybridomas to produce mAbs, which is time-consuming and may not yield the desired mAb. We recommend a process flow for affinity reagent production that utilizes combinatorial protein display systems (eg, yeast surface display or phage display) rather than hybridomas. These systems link a selectable phenotype—binding conferred by an antibody fragment—with a means for recovering the encoding gene. Recombinant libraries obtained from immunizations can produce high-affinity antibodies (
Revised: October 13, 2011 |
Published: October 1, 2010
Citation
Baird C.L., C.J. Fischer, N.B. Pefaur, K.D. Miller, J. Kagen, S. Srivastava, and K.D. Rodland. 2010.Developing recombinant antibodies for biomarker detection.Cancer Biomarkers 6, no. 5-6:271-279.PNNL-SA-73330.doi:10.3233/CBM-2009-0144